NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

IMAB

I-Mab ADR

Jun 30 • 04:00PM ET

2.42

Dollar change -0.15
Percentage change -5.84	%

Healthcare • Biotechnology • USA • NASD

Peers: ONC ZLAB LEGN HCM TME CANF OCGN BBIO MRNA RGEN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.71	Insider Own	0.27%	Shs Outstand	78.94M	Perf Week	-1.63%
Market Cap	191.03M	Forward P/E	-	EPS next Y	-0.35	Insider Trans	0.00%	Shs Float	78.72M	Perf Month	92.06%
Enterprise Value	26.09M	PEG	-	EPS next Q	-0.05	Inst Own	11.85%	Short Float	0.48%	Perf Quarter	187.65%
Income	-56.51M	P/S	-	EPS this Y	-80.00%	Inst Trans	-42.89%	Short Ratio	0.71	Perf Half Y	168.89%
Sales	0.00M	P/B	1.00	EPS next Y	-62.04%	ROA	-17.08%	Short Interest	0.38M	Perf YTD	184.71%
Book/sh	2.43	P/C	1.13	EPS next 5Y	-	ROE	-22.38%	52W High	3.08 -21.30%	Perf Year	41.94%
Cash/sh	2.14	P/FCF	-	EPS past 3/5Y	47.29% 28.36%	ROIC	-28.09%	52W Low	0.60 306.72%	Perf 3Y	-79.82%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	25.78% 19.32%	Perf 5Y	-91.92%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	72.51%	Oper. Margin	-	ATR (14)	0.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	22.35	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	56.37	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	22.35	EPS Q/Q	93.60%	SMA20	2.72%	Beta	1.40	Target Price	5.60
Payout	-	Debt/Eq	0.02	Sales Q/Q	-100.00%	SMA50	61.14%	Rel Volume	1.11	Prev Close	2.57
Employees	32	LT Debt/Eq	0.01	Earnings	May 15 BMO	SMA200	112.61%	Avg Volume	537.24K	Price	2.42
IPO	Jan 17, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	68.40% -	Trades		Volume	592,235	Change	-5.84%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-21	Initiated	Siebert Williams Shank	Buy	$96
Jun-02-21	Initiated	Daiwa Securities	Buy
Mar-15-21	Initiated	Needham	Buy	$75
Mar-03-21	Reiterated	H.C. Wainwright	Buy	$55 → $75
Feb-25-21	Initiated	Piper Sandler	Overweight	$75
Dec-07-20	Initiated	H.C. Wainwright	Buy	$55
Jul-27-20	Initiated	Cantor Fitzgerald	Overweight	$50
Feb-12-20	Initiated	China Renaissance	Buy
Feb-11-20	Initiated	Jefferies	Buy	$16

Jun-30-25 04:01PM	I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research (GlobeNewswire) -5.84%
Jun-26-25 06:30AM	I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 (GlobeNewswire) -27.34%
Jun-18-25 07:00AM	I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025 (GlobeNewswire) -5.67%
Jun-12-25 07:00AM	I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jun-11-25 09:55AM	I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross (Zacks) -5.68%
12:00PM	Loading…
Jun-06-25 12:00PM	I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy? (Zacks) +6.99%
Jun-03-25 07:00AM	I-Mab to Participate in the H.C. Wainwright "HCW@Home" Series (GlobeNewswire) +46.09%
May-20-25 07:00AM	I-Mab to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 07:00AM	I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-30-25 07:00AM	I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025 (GlobeNewswire) +15.76%
Apr-14-25 09:35AM	After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) (Zacks) +42.81%
Apr-11-25 09:35AM	After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) (Zacks)
Apr-03-25 04:01PM	I-Mab Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.19% -6.86%
Mar-26-25 07:00AM	I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-25 04:30PM	I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire)
07:00AM	Loading…
Mar-07-25 07:00AM	I-Mab Announces Accelerated Givastomig Phase 1b Study Progress (GlobeNewswire)
Feb-18-25 07:00AM	I-Mab to Participate in Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-04-25 07:30AM	I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-08-25 07:00AM	I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member (PR Newswire) +11.97%
Jan-07-25 05:38AM	I-Mab pauses CD73 antibody development in pipeline reshuffle (Clinical Trials Arena) -9.04%
Jan-06-25 07:00AM	I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program (PR Newswire) +14.91%
Nov-21-24 07:00AM	I-Mab to Participate at the Piper Sandler Healthcare Conference (PR Newswire)
Nov-14-24 07:00AM	I-Mab Reports Third Quarter 2024 Results (PR Newswire)
Nov-06-24 07:00AM	I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer (PR Newswire)
Oct-31-24 07:00AM	I-Mab to Release Q3 2024 Financial Results on November 14, 2024 (PR Newswire)
Oct-30-24 07:00AM	I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024 (PR Newswire) -5.93%
Oct-28-24 07:00AM	I-Mab to Participate at the Truist Securities BioPharma Symposium (PR Newswire)
Oct-25-24 07:28AM	I-Mab Biopharmas Strategic US Transition and Pipeline Focus (TipRanks)
Oct-09-24 12:00PM	IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Sep-16-24 04:01PM	I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024 (PR Newswire)
07:00AM	Loading…
Sep-10-24 07:00AM	I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer (PR Newswire)
Aug-28-24 07:00AM	I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates (PR Newswire) -7.14%
Aug-26-24 07:00AM	I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +7.00%
Aug-14-24 07:00AM	I-Mab to Release 1H 2024 Financial Results on August 28, 2024 (PR Newswire)
Aug-07-24 07:00AM	I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC) (PR Newswire)
Jul-15-24 07:30AM	I-Mab Announces Leadership Transitions (PR Newswire) -5.23%
Jun-06-24 07:00AM	I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer (PR Newswire)
04:45AM	I-Mab and BMS assess givastomig for gastric and oesophageal cancer (Pharmaceutical Technology)
Jun-05-24 07:00AM	I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers (PR Newswire)
May-23-24 05:05PM	I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024 (GlobeNewswire)
May-22-24 07:00AM	I-Mab to Participate at the Jefferies Global Healthcare Conference (PR Newswire)
May-02-24 12:00AM	Q1 2024 Summit Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-30-24 07:00AM	I-MAB Filed 2023 Annual Report on Form 20-F (PR Newswire)
Apr-05-24 07:00AM	I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference (PR Newswire)
Apr-02-24 04:01PM	I-Mab Announces Closing of the Divestiture of Business Operations in China (PR Newswire)
Mar-14-24 05:00PM	I-Mab Reports Full Year 2023 Financial Results and Business Update (PR Newswire)
Mar-07-24 10:03AM	TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-21-24 01:56AM	Q4 2023 Summit Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-07-24 08:28AM	I-Mab sheds China footprint to complete transformation into US-based biotech (FierceBiotech.com)
06:29AM	UPDATE 2-Biotech firm I-Mab to divest China operations, shift focus to US (Reuters)
06:00AM	I-Mab Signs Agreement to Divest its Assets and Business Operations in China (PR Newswire)
Nov-06-23 08:00AM	I-Mab Announces Participation at Jefferies and Piper Conferences in November (PR Newswire)
Nov-02-23 08:00AM	Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN) (PR Newswire) +9.15%
Nov-01-23 08:00AM	I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023 (PR Newswire) +6.99%
Oct-16-23 08:00AM	I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023 (PR Newswire)
Oct-10-23 08:00AM	I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503 (PR Newswire) +6.38%
Oct-05-23 05:17PM	Ray Dalio on Potential US-China War and Rise of China (Insider Monkey) +6.11% +5.04%
Sep-22-23 05:03PM	UPDATE 1-AbbVie terminates deal with I-Mab to develop cancer drug (Reuters) +6.67%
Sep-05-23 08:00AM	I-Mab Announces Upcoming Participation at September Conferences (PR Newswire) -7.73%
Aug-18-23 10:55AM	I-Mab (NASDAQ:IMAB) Q2 2023 Earnings Call Transcript (Insider Monkey) -8.70%
Aug-17-23 10:30PM	Half Year 2023 I-Mab Earnings Call (Thomson Reuters StreetEvents)
06:00AM	I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates (PR Newswire)
05:25AM	Analyst Report: I-Mab (Morningstar Research)
Aug-08-23 08:00AM	I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023 (PR Newswire)
Jul-07-23 06:35PM	Masimo and Vera Therapeutics Stock See Action From Activist Investors (Barrons.com)
Jul-05-23 08:00AM	I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC (PR Newswire)
Jun-22-23 08:00AM	I-Mab Announces the Appointment of Raj Kannan as CEO (PR Newswire)
Jun-11-23 10:31AM	Retail investors account for 40% of I-Mab's (NASDAQ:IMAB) ownership, while institutions account for 17% (Simply Wall St.)
May-26-23 10:00AM	I-Mab Reveals Promising Results in Phase 1b/2 Study for Advanced Non-Small Cell Lung Cancer Treatment (Benzinga)
May-25-23 05:01PM	I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 (PR Newswire) -5.97%
May-01-23 08:00AM	I-MAB Filed 2022 Annual Report on Form 20-F (PR Newswire)
Apr-26-23 09:16AM	I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023 (PR Newswire) -5.73%
Apr-25-23 01:46AM	I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon (PR Newswire)
Apr-24-23 09:00AM	I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China (PR Newswire) -5.07%
Apr-05-23 10:59AM	Analyst Report: I-Mab (Morningstar Research)
10:51AM	I-Mab (NASDAQ:IMAB) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-31-23 06:30AM	I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 (PR Newswire)
Mar-20-23 08:00AM	I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023 (PR Newswire)
Mar-10-23 02:26AM	TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 05:49AM	Q4 2022 TRACON Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -6.05%
Mar-07-23 08:02AM	MSCI ESG Updated I-Mab to "A" Rating (PR Newswire)
Feb-25-23 07:14AM	We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate (Simply Wall St.)
Jan-29-23 07:07AM	Shareholders in I-Mab (NASDAQ:IMAB) are in the red if they invested a year ago (Simply Wall St.)
Jan-02-23 06:14AM	Positive week for I-Mab (NASDAQ:IMAB) institutional investors who lost 91% over the past year (Simply Wall St.)
Nov-12-22 08:21AM	I-Mab First Half 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-03-22 09:01AM	I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022 (PR Newswire)
Oct-05-22 08:00AM	I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022 (PR Newswire)
Sep-13-22 08:00AM	I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome (PR Newswire)
Sep-10-22 09:00AM	I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022 (PR Newswire)
Sep-06-22 08:00AM	I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022 (PR Newswire) -5.41%
Aug-30-22 06:00AM	I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022 (PR Newswire)
Aug-23-22 09:13AM	I-Mab Announces Share Purchase Plans by the Company and the Senior Management (PR Newswire)
Aug-20-22 08:26AM	What You Need To Know About The I-Mab (NASDAQ:IMAB) Analyst Downgrade Today (Simply Wall St.)
Aug-19-22 09:00AM	I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022 (PR Newswire)
Aug-18-22 12:38PM	I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal (Zacks) -9.37%
Aug-17-22 03:24PM	This Analyst Cuts I-Mab's Price Target By 43% (Benzinga) -14.30%
10:19AM	AbbVie Calls Off Early-Stage Trial For I-Mab's CD47-Targeted Blood Cancer Candidate (Benzinga)
Aug-02-22 09:04AM	10 52-Week Low Stocks to Buy Now (Insider Monkey)
Jul-22-22 08:00AM	I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China (PR Newswire) -5.39%
Jul-18-22 08:00AM	I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022 (PR Newswire)

I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KANNAN RAJ	Officer	Jul 26 '24	Proposed Sale	1.39	50,000	69,500		Jul 26 06:20 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMAB

I-Mab ADR

Upgrade your FINVIZ experience